NasdaqGS - Delayed Quote USD

Halozyme Therapeutics, Inc. (HALO)

53.31
-2.33
(-4.19%)
At close: June 3 at 4:00:01 PM EDT
53.49
+0.18
+(0.34%)
After hours: June 3 at 7:59:57 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,084,306
1,015,324
829,253
660,116
443,310
Cost of Revenue
179,491
159,417
192,361
139,304
81,413
Gross Profit
904,815
855,907
636,892
520,812
361,897
Operating Expense
307,347
304,432
299,318
253,281
85,995
Operating Income
597,468
551,475
337,574
267,531
275,902
Net Non Operating Interest Income Expense
-18,113
-18,095
-18,762
-16,947
-7,526
Other Income Expense
25,577
23,752
29,517
-1,666
-19,858
Pretax Income
604,932
557,132
348,329
248,918
248,518
Tax Provision
119,569
113,041
66,735
46,789
-154,192
Net Income Common Stockholders
485,363
444,091
281,594
202,129
402,710
Diluted NI Available to Com Stockholders
485,363
444,091
281,594
202,129
402,710
Basic EPS
3.85
3.50
2.13
1.48
2.86
Diluted EPS
3.76
3.43
2.10
1.44
2.74
Basic Average Shares
125,895.50
126,827
131,927
136,844
140,646
Diluted Average Shares
128,863.25
129,424
134,197
140,608
146,796
Total Operating Income as Reported
597,468
551,475
337,574
267,531
275,902
Total Expenses
486,838
463,849
491,679
392,585
167,408
Net Income from Continuing & Discontinued Operation
485,363
444,091
281,594
202,129
402,710
Normalized Income
464,841.47
425,158.28
257,723.60
203,481.79
417,206.34
Interest Expense
18,113
18,095
18,762
16,947
7,526
Net Interest Income
-18,113
-18,095
-18,762
-16,947
-7,526
EBIT
623,045
575,227
367,091
265,865
256,044
EBITDA
704,600
656,539
451,947
315,506
259,041
Reconciled Cost of Revenue
168,984
149,154
181,278
132,811
78,416
Reconciled Depreciation
81,555
81,312
84,856
49,641
2,997
Net Income from Continuing Operation Net Minority Interest
485,363
444,091
281,594
202,129
402,710
Total Unusual Items Excluding Goodwill
25,577
23,752
29,517
-1,666
-19,858
Total Unusual Items
25,577
23,752
29,517
-1,666
-19,858
Normalized EBITDA
679,023
632,787
422,430
317,172
278,899
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
5,055.47
4,819.28
5,646.60
-313.21
-5,361.66
12/31/2021 - 3/16/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EXEL Exelixis, Inc.
42.67
-0.49%
 
CORT Corcept Therapeutics Incorporated
69.51
-3.03%
 
CPRX Catalyst Pharmaceuticals, Inc.
24.91
+0.04%
 
ADMA ADMA Biologics, Inc.
20.46
+0.15%
 
ARVN Arvinas, Inc.
7.00
-4.50%
 
HRMY Harmony Biosciences Holdings, Inc.
35.31
-0.70%
 
ARGX argenx SE
576.61
-1.37%
 
INCY Incyte Corporation
67.11
+2.76%
 
RVMD Revolution Medicines, Inc.
40.58
-0.17%
 
ACAD ACADIA Pharmaceuticals Inc.
21.98
+2.40%